<em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumon...

Descripción completa

Detalles Bibliográficos
Autores principales: Ergenç, İlkay, Şanal Toprak, Canan, Odabaşı, Zekaver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607000/
https://www.ncbi.nlm.nih.gov/pubmed/34870129
http://dx.doi.org/10.5606/tftrd.2021.8208
_version_ 1784602458830405632
author Ergenç, İlkay
Şanal Toprak, Canan
Odabaşı, Zekaver
author_facet Ergenç, İlkay
Şanal Toprak, Canan
Odabaşı, Zekaver
author_sort Ergenç, İlkay
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
format Online
Article
Text
id pubmed-8607000
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bayçınar Medical Publishing
record_format MEDLINE/PubMed
spelling pubmed-86070002021-12-02 <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab Ergenç, İlkay Şanal Toprak, Canan Odabaşı, Zekaver Turk J Phys Med Rehabil Case Report Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab. Bayçınar Medical Publishing 2021-09-01 /pmc/articles/PMC8607000/ /pubmed/34870129 http://dx.doi.org/10.5606/tftrd.2021.8208 Text en Copyright © 2021, Turkish Society of Physical Medicine and Rehabilitation https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Ergenç, İlkay
Şanal Toprak, Canan
Odabaşı, Zekaver
<em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title_full <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title_fullStr <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title_full_unstemmed <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title_short <em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab
title_sort <em>staphylococcus aureus costochondritis</em> and chest wall abscess in a covid-19 patient treated with tocilizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607000/
https://www.ncbi.nlm.nih.gov/pubmed/34870129
http://dx.doi.org/10.5606/tftrd.2021.8208
work_keys_str_mv AT ergencilkay emstaphylococcusaureuscostochondritisemandchestwallabscessinacovid19patienttreatedwithtocilizumab
AT sanaltoprakcanan emstaphylococcusaureuscostochondritisemandchestwallabscessinacovid19patienttreatedwithtocilizumab
AT odabasızekaver emstaphylococcusaureuscostochondritisemandchestwallabscessinacovid19patienttreatedwithtocilizumab

Ejemplares similares